L
Laurent Billot
Researcher at The George Institute for Global Health
Publications - 6
Citations - 88
Laurent Billot is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Randomized controlled trial & Clinical endpoint. The author has an hindex of 2, co-authored 6 publications receiving 6 citations.
Papers
More filters
Journal ArticleDOI
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Clara K Chow,Emily Atkins,Emily Atkins,Graham S Hillis,Mark Nelson,Christopher M. Reid,Christopher M. Reid,Markus P. Schlaich,Peter Hay,Kris Rogers,Kris Rogers,Laurent Billot,Michael Burke,John Chalmers,Bruce Neal,Bruce Neal,Anushka Patel,Tim Usherwood,Tim Usherwood,Ruth Webster,Ruth Webster,Anthony Rodgers,Andrew Hung,Armand Edison,Angalie E Abraham,Dan Xu,Mark Bloch,Gemma A. Figtree,Janis M. Nolde,Andrew Black,Shirley Jansen,Sinjini Biswas,Andrew E. Ajani,Revathy Carnagarin,D. Wynne,M. Altman,Jay Thakkar,Aravinda Thiagalingam,Harry Klimis +38 more
TL;DR: The QUARTET trial as discussed by the authors showed that a hypertension management strategy starting with a single pill containing ultra-low-dose quadruple combination therapy would be more effective than a strategy of starting with monotherapy.
Journal ArticleDOI
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Muh Geot Wong,Jicheng Lv,Michelle A. Hladunewich,Vivekanand Jha,Lai Seong Hooi,Helen Monaghan,Ming-Hui Zhao,Sean J. Barbour,Heather N. Reich,Daniel C. Cattran,Richard J. Glassock,Adeera Levin,Meg Jardine,David C. Wheeler,Mark Woodward,Laurent Billot,Tak Mao Chan,Zhihong Liu,David W. Johnson,Alan Cass,John Feehally,Jürgen Floege,Giuseppe Remuzzi,Yangfeng Wu,Rajiv Agarwal,Hong Zhang,Vlado Perkovic +26 more
TL;DR: The Therapeutic Evaluation of STeroids in IgA Nephropathy Global (TESTING) study as discussed by the authors was designed to assess the benefits and risks of steroids in people with IgAN.
Journal ArticleDOI
Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network
Rachelle Buchbinder,Allison Bourne,Jane Latimer,Ian A. Harris,Samuel L Whittle,Bethan Richards,William J. Taylor,Ornella Clavisi,Sally Green,Rana S Hinman,Lyn March,Richard O. Day,Manuela L. Ferreira,Laurent Billot,Christopher G. Maher +14 more
TL;DR: The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network was formed to build capacity and infrastructure for high‐quality clinical trials in the authors' region to help others interested in establishing similar networks.
Journal ArticleDOI
Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease.
Kristen J. Bubb,Kristen J. Bubb,Jason A. Harmer,Jason A. Harmer,Meghan Finemore,Meghan Finemore,Sarah J. Aitken,Sarah J. Aitken,Zara S Ali,Zara S Ali,Laurent Billot,Clara K Chow,Jonathan Golledge,Rebecca Mister,Michael P Gray,Michael P Gray,Stuart M. Grieve,Stuart M. Grieve,Stuart M. Grieve,Naomi M. Hamburg,Anthony C Keech,Sanjay Patel,Vikram Puttaswamy,Gemma A. Figtree,Gemma A. Figtree,Gemma A. Figtree +25 more
TL;DR: The Star-PAD trial as mentioned in this paper is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD.